Follicular Lymphoma, Mantle Cell Lymphoma Clinical Trial
Official title:
A Phase Ib Dose Escalation Study of BCL201 in Combination With Idelalisib in Patients With Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)
| Verified date | February 2020 |
| Source | Novartis |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This is a phase Ib multi-center, open-label study: escalation part followed by expansion
part. The primary purpose of the Phase Ib CBCL201X2102C study is to characterize the safety
and tolerability of BCL201 combined with idelalisib in patients with FL and MCL.
Approximately 65 patients are to be enrolled.
The primary endpoint for the Phase Ib is frequency, severity and seriousness of AEs, lab
abnormalities and other safety parameters such as ECG changes. An adaptive Bayesian logistic
regression model (BLRM) will guide the dose escalation to determine the MTD/RDE in phase Ib.
In addition Bayesian regression models will be used to estimate the dose-exposure
relationships for both BCL201 and idelalisib in order to guide the escalation steps. A
Bayesian method for the expansion part will be used for the primary activity objective.
The study data will be analyzed and reported based on all patients' data of the escalation
and expansion part.
| Status | Completed |
| Enrollment | 20 |
| Est. completion date | July 10, 2018 |
| Est. primary completion date | July 10, 2018 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Histologically confirmed diagnosis of FL or MCL according to WHO 2008 - Relapsed or refractory with at least one (FL) or two (MCL), but not more than four, prior lines of antineoplastic regimens. - Either FDG-avid on FDG-PET or measurable disease by CT on cross sectional imaging: > 1.5 cm for nodal lesion, > 1.0 cm for extra nodal lesion. - Eastern Cooperative Oncology Group (ECOG) performance status of = 2 Exclusion Criteria: - For dose escalation part: Patients with MCL at high risk for tumor lysis syndrome - Prior treatment with PI3Kd or Bcl-2 inhibitors. - Any other malignant disease - History of serious allergic reactions including anaphylaxis and toxic epidermal necrolysis - Inadequate organ function - Concomitant treatment with: - Strong CYP3A4/5 inducers or inhibitors - Sensitive CYP3A4/5 substrates or CYP3A4/5 substrates with narrow therapeutic index (NTI) - Sensitive CYP2D6 substrates or CYP2D6 substrates with NTI - Selected dual substrates of CYP3A4/5 and CYP2C8 - Selected dual substrates of CYP3A4/5 and CYP2D6 - Selected dual substrates of OATP and CYP450 - Selected dual substrates of CYP3A4/5 and P-gp - NTI P-gp substrates - QT prolonging drugs with a known risk to induce TdP - Proton pump inhibitors - Treatment by warfarin or equivalent vitamin K antagonists. - Other investigational therapies - Herbal preparations/ medications - Grapefruit, Seville oranges or products containing either juice Other protocol-defined inclusion/exclusion may apply. |
| Country | Name | City | State |
|---|---|---|---|
| Austria | Novartis Investigative Site | Salzburg | |
| France | Novartis Investigative Site | Pierre Benite Cedex | |
| France | Novartis Investigative Site | Toulouse Cedex 9 | |
| Germany | Novartis Investigative Site | Freiburg | |
| Germany | Novartis Investigative Site | Mainz | |
| United States | Novartis Investigative Site | Houston | Texas |
| United States | Novartis Investigative Site | New York | New York |
| Lead Sponsor | Collaborator |
|---|---|
| Novartis Pharmaceuticals |
United States, Austria, France, Germany,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number of participants with adverse events (AEs) | Characterized by Frequency, severity and seriousness of AEs, lab abnormalities and other safety parameters such as electrocardiogram (ECG) changes | 24 months | |
| Secondary | Incidence rate of dose limiting toxicities (DLTs) | 24 months | ||
| Secondary | Exposure to BCL201 and idelalisib as measured by AUC0-24h at C1D15 | Cycle = 28 days | ||
| Secondary | Plasma concentration of BCL201, idelalisib and GS-563117 (metabolite of idelalisib) | 24 Months | ||
| Secondary | AUC pharmacokinetics (PK) parameter for BCL201, idelalisib and GS-563117 | 24 months | ||
| Secondary | Objective Response Rate (ORR) | 24 months | ||
| Secondary | Best Overall Response (BOR) | 24 months | ||
| Secondary | Duration of Response (DOR) | 24 months | ||
| Secondary | Complete Response (CR) | 24 months | ||
| Secondary | Partial Response (PR) | 24 months | ||
| Secondary | Stable disease (SD) | 24 months | ||
| Secondary | Cmax pharmacokinetics (PK) parameter for BCL201, idelalisib and GS-563117 | 24 months |